M Stahl
Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
Ruhstaller T, Langer R, Thuss-Patience P, Eisterer W, Stahl M. Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu. Ann Oncol 2018
Jul 9, 2018Reply to the letter to the editor "Anti-EGFR therapy in oesophagogastric cancer: precise but not enough" by M. Salati and S. Cascinu
Jul 9, 2018Ann Oncol 2018
Ruhstaller Thomas, Langer R, Thuss-Patience P, Eisterer W, Stahl M
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
Jun 1, 2018Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Jun 1, 2018Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
[Combined modality treatment of oesophageal cancer]
Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014; 55:7-14.
Jan 1, 2014[Combined modality treatment of oesophageal cancer]
Jan 1, 2014Internist (Berl) 2014; 55:7-14
Stahl M, Ruhstaller Thomas